Sclerotherapy of liver hemangioma
Phase 1
Completed
- Conditions
- iver symptomatic hemangioma.Haemangioma, any site
- Registration Number
- IRCT2016021626599N1
- Lead Sponsor
- Vice Chancellor for Research, Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 5
Inclusion Criteria
Patients with symptomatic liver hemangioma with therapeutic indication with confirmed diagnosis based on triphasic CT-scan or dynamic MRI.
Exclusion criteria: Those patients that their abdominal complaints could be attributed to another cause, apart from liver hemangioma
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Volume of lesion. Timepoint: 6 month after therapy. Method of measurement: Digital volumetry.
- Secondary Outcome Measures
Name Time Method Abdominal pain. Timepoint: one month and 6 month after procedure. Method of measurement: visual analog scale.